Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma

DOI: 10.7150/thno.25487

Keywords: cancer stem cells, hepatocellular carcinoma, PDX models, CDK1 inhibitor, RO3306, sorafenib

Full-Text   Cite this paper   Add to My Lib

Abstract:

Rationale: Hepatocellular carcinoma (HCC) is an aggressive malignant solid tumor wherein CDK1/PDK1/β-Catenin is activated, suggesting that inhibition of this pathway may have therapeutic potential.

Full-Text